Quantcast

Latest Orphan drugs Stories

2014-06-09 12:26:41

Public Healthcare Systems in Brazil and Mexico Cover Targeted Therapies but with Indication-Specific Restrictions, According to Findings from Decision Resources Group BURLINGTON, Mass., June 9, 2014 /PRNewswire/ -- Decision Resources Group finds that targeted therapies such as MabThera (rituximab) for non-Hodgkin's lymphoma (NHL) and Velcade (bortezomib) for multiple myeloma (MM) enjoy extensive but incomplete coverage in Brazil and Mexico through complex mechanisms. To obtain reimbursement,...

2014-06-02 12:28:29

High Cost and High Expectations for Clinical Benefits are Major Market Access Hurdles Facing New CML Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., June 2, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed hematologists in China estimate that Novartis's Glivec (imatinib) will lose nearly half of its patient share for treatment of chronic myeloid leukemia (CML) in the next three years, due to the market entry of generic imatinib. Nevertheless,...

2014-05-30 08:25:14

Retrospective Analysis Demonstrates Survival Benefits for Patients with Stable and Progressive Disease after HD IL-2 in the Modern Era Suggesting Appropriate Drug Sequencing May Improve Outcomes CHICAGO, May 30, 2014 /PRNewswire/ -- Prometheus Laboratories Inc. announced today that analysis of data from the PROCLAIM(SM) national patient registry retrospective cohort shows improved overall survival in metastatic RCC patients treated with high-dose Proleukin(®) (aldesleukin) in the...

2014-05-27 16:25:23

New Data Reinforces Commitment to Personalized Medicine and Highlights Advances in Immunotherapy Platform THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 27, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced data from several studies of both pipeline and marketed products will be presented at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30-June 3 in Chicago. The research that will...

2014-05-27 12:32:14

Robust Value Dossiers and Smart Uptake Strategies are Vital to Secure Optimal Market Access in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., May 27, 2014 /PRNewswire/ -- Decision Resources Group finds that Novartis's Glivec is the clear agent of choice for first-line treatment of chronic myelogenous leukemia (CML) patients in the chronic phase, according to surveyed hematological oncologists from France, Germany, Italy, Spain and the United Kingdom (EU5). Use...

2014-05-14 20:23:42

Data underscore breadth of oncology portfolio WOODCLIFF LAKE, N.J., May 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2014. "Anchored by our human health care mission, Eisai's commitment to cancer patients and their families is evidenced by our focus on sometimes overlooked patient...

2014-05-14 16:29:06

WHIPPANY, N.J., May 14, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data from its oncology portfolio, including NEXAVAR(®) (sorafenib) tablets, Xofigo(®) (radium Ra 223 dichloride) injection and Stivarga(®) (regorafenib) tablets, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 - June 3, in Chicago, IL (USA). Bayer will also present data from its late stage clinical pipeline, investigating...

2014-05-12 23:08:41

Pulmonary arterial hypertension – a deadly, incurable lung condition – is one of only sixteen disease states FDA will focus on during the first three years of the Patient Focused Drug Development Initiative. The meeting represents a historic opportunity for patient input. Silver Spring, MD (PRWEB) May 12, 2014 On Tuesday, May 13, the Food and Drug Administration and the Pulmonary Hypertension Association will host a unique conversation between FDA drug reviewers and pulmonary arterial...

2014-05-07 12:29:49

Personalized Drug Treatment Will Emerge for HCC with the Approval of a Novel Biomarker-Targeted Agent, According to Findings from Decision Resources Group BURLINGTON, Mass., May 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the treatment landscape of hepatocellular carcinoma (HCC) will change dramatically through 2023 as new therapies gain approval and launch for second-line treatment of advanced HCC following disease progression/intolerance to first-line Nexavar (Bayer...

2014-04-29 23:11:40

CML-IQ delivers timely, accurate information to help people make informed decisions. Montreal, QC (PRWEB) April 29, 2014 Every day in North America, about 16 people are diagnosed with a form of blood cancer called chronic myelogenous leukemia (CML). This disease is characterized by an abnormal proliferation of white blood cells, which results in bruising, a swollen spleen and bleeding complications. Until recently, life expectancy was only a few years for people diagnosed with CML. That...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related